Oracle and Baylor College of Medicine Collaborate to Advance Research into Alcohol-related Liver Disease
Oracle Health and Baylor College of Medicine (ORCL) announced a collaboration on Oct 21, 2025 to advance research into alcohol-related liver disease (ALD). Baylor will leverage Oracle Health's AI data platform and real-world data of more than 120 million longitudinal anonymized patient records to build one of the nation's largest ALD cohorts.
Baylor plans to expand its ALD real-world data cohort to more than one million patients using Oracle's datasets and research-ready AI agents to identify predictive markers, improve early detection, and inform prevention and treatment strategies.
Oracle Health e Baylor College of Medicine (ORCL) hanno annunciato una collaborazione il 21 ottobre 2025 per avanzare la ricerca sulla malattia del fegato correlata all'alcol (ALD). Baylor utilizzerà la piattaforma dati AI di Oracle Health e i dati real-world di oltre 120 milioni registri di pazienti longitudinali anonimi per costruire uno dei più grandi coorti ALD del paese.
Baylor intende espandere il proprio cohort di dati real-world sull'ALD a oltre un milione di pazienti utilizzando i set di dati di Oracle e agenti AI pronti per la ricerca per identificare marcatori predittivi, migliorare la rilevazione precoce e informare strategie di prevenzione e trattamento.
Oracle Health y Baylor College of Medicine (ORCL) anunciaron una colaboración el 21 de octubre de 2025 para avanzar en la investigación sobre la enfermedad hepática relacionada con el alcohol (ALD). Baylor aprovechará la plataforma de datos de IA de Oracle Health y los datos del mundo real de más de 120 millones de historiales longitudinales de pacientes anonimizados para construir uno de los mayores cohortes de ALD del país.
Baylor planea ampliar su cohorte de datos del mundo real de ALD a más de un millón de pacientes utilizando los conjuntos de datos de Oracle y agentes de IA listos para la investigación para identificar marcadores predictivos, mejorar la detección temprana e informar las estrategias de prevención y tratamiento.
Oracle Health와 Baylor College of Medicine(ORCL)은 2025년 10월 21일 ALD(음주 관련 간질환) 연구를 진전시키기 위한 협력을 발표했습니다. Baylor는 Oracle Health의 AI 데이터 플랫폼과 1억 2천만 명이 넘는 장기적 익명 환자 기록의 실제 세계 데이터를 활용하여 미국에서 가장 큰 ALD 코호트 중 하나를 구축할 예정입니다.
Baylor는 Oracle의 데이터 세트와 연구용 AI 에이전트를 사용하여 예측 마커를 식별하고 조기 발견을 개선하며 예방 및 치료 전략을 안내하기 위해 ALD의 실제 세계 데이터 코호트를 100만 명 이상으로 확장할 계획입니다.
Oracle Health et le Baylor College of Medicine (ORCL) ont annoncé une collaboration le 21 octobre 2025 pour faire progresser la recherche sur la maladie du foie liée à l’alcool (ALD). Baylor utilisera la plateforme de données IA d’Oracle Health et les données réelles de plus de 120 millions de dossiers patients anonymisés pour construire l’un des plus grands cohortes ALD du pays.
Baylor prévoit d’étendre sa cohorte de données réelles ALD à plus d’un million de patients en utilisant les jeux de données d’Oracle et des agents IA prêts pour la recherche afin d’identifier des marqueurs prédictifs, d’améliorer la détection précoce et d’informer les stratégies de prévention et de traitement.
Oracle Health und das Baylor College of Medicine (ORCL) haben am 21. Oktober 2025 eine Zusammenarbeit angekündigt, um die Forschung zur alkoholbedingten Lebererkrankung (ALD) voranzutreiben. Baylor wird die KI-Datenplattform von Oracle Health und die Real-World-Daten von mehr als 120 Millionen longitudinalen, anonymisierten Patientenakten nutzen, um eine der größten ALD-Kohorten des Landes zu erstellen.
Baylor plant, seine Real-World-Datenkohorte zu ALD auf mehr als eine Million Patienten auszuweiten, indem es Oracles Datensätze und forschungsbereite KI-Agenten verwendet, um vorhersehbare Marker zu identifizieren, die Früherkennung zu verbessern und Präventions- und Behandlungsstrategien zu informieren.
Oracle Health وبايلور كولج للطب (ORCL) قد أعلنا عن تعاون في 21 أكتوبر 2025 لتعزيز البحث في مرض الكبد المرتبط بالكحول (ALD). ستستخدم Baylor منصة بيانات الذكاء الاصطناعي الخاصة بـ Oracle Health وبيانات العالم الواقعي لأكثر من مائة ومئتين مليون سجلّاً للمرضى مجهول الهوية بشكل طولي لبناء واحد من أكبر مجموعات ALD في البلاد.
تخطط Baylor لتوسيع مجموعتها من بيانات العالم الواقعي لـ ALD إلى أكثر من مليون مريض باستخدام مجموعات بيانات Oracle ووكلاء ذكاء اصطناعي جاهزين للبحث لتحديد علامات التنبؤ، وتحسين الكشف المبكر، وإبلاغ استراتيجيات الوقاية والعلاج.
Oracle Health 与 Baylor 医学院（ORCL） 于 2025 年 10 月 21 日 宣布合作，以推进酒精相关肝病（ALD）的研究。Baylor 将利用 Oracle Health 的 AI 数据平台以及超过 1.2 亿 条纵向匿名患者真实世界数据，构建美国最大的 ALD 队列之一。
Baylor 计划使用 Oracle 的数据集与面向研究的 AI 代理，将 ALD 的真实世界数据队列扩展到 超过一百万名患者，以识别预测性标志物、改善早期检测，并为预防和治疗策略提供依据。
- Access to 120 million anonymized longitudinal patient records
- Plan to grow ALD real-world data cohort to >1 million patients
- Use of research-ready AI agents to identify predictive markers
- Aim to enable earlier identification and improved ALD treatment strategies
- None.
Insights
Partnership uses Oracle Health RWD to build a large ALD cohort for earlier detection and research.
The collaboration pairs Oracle Health data and AI tools with Baylor College of Medicine clinical research capacity to assemble a research cohort exceeding one million patients from an existing anonymized repository of more than 120 million longitudinal records. This creates a sizable dataset designed to surface patterns, risk factors, and predictive markers for alcohol-related liver disease that are otherwise hard to detect in smaller datasets.
Key dependencies include data quality, cohort definition, and governance; success requires clear phenotyping rules, robust de-identification, and reproducible analytic pipelines. Clinical utility will depend on whether the derived signals translate into validated diagnostic markers or care pathways; partnership announcements alone do not confirm those outcomes.
Watch for concrete milestones such as the dataset release or cohort definition, validation of predictive markers, and any peer-reviewed results over the next 12–36 months. The impact on research and care will hinge on published validation and integration of insights into clinical workflows rather than the announcement itself.
Through this collaboration, Baylor College of Medicine plans to leverage Oracle Health's AI data platform and real-world data (RWD), containing more than 120 million longitudinal anonymized patient records, to establish one of the nation's largest ALD cohorts. Using Oracle Health solutions, Baylor College of Medicine plans to increase its RWD cohort to more than one million patients to support research that is expected to lead to earlier identification of ALD, deepen understanding of disease progression, and ultimately inform more effective prevention and treatment strategies.
"Alcohol-related liver disease represents a critical public health challenge, and earlier identification is key to changing outcomes," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "With Oracle's robust data and analytics capabilities and Baylor's expertise in clinical research and patient care, we have the opportunity to help transform how this condition is studied, diagnosed, and treated."
Baylor College of Medicine researchers plan to use Oracle's comprehensive datasets and research-ready AI agents to uncover patterns, risk factors, and predictive markers of disease progression. The goal is to empower clinicians with actionable insights that can improve patient outcomes while also supporting public health strategies to reduce the burden of ALD nationwide.
"Our work with Oracle represents an exciting opportunity to accelerate discovery and improve clinical practice in the era of digital medicine," said Dr. Hashem El-Serag, Vice President for the Learning Health System Initiative and Professor and Chair of the Department of Medicine, Baylor College of Medicine. "By building one of the largest alcohol-related liver disease cohorts in the country, we're not only creating a critical research resource, but also advancing the potential to intervene earlier and more effectively for patients at risk."
Recent studies indicate that alcohol-related liver disease has been on the rise in the
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
About Baylor College of Medicine
Baylor College of Medicine in
View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-baylor-college-of-medicine-collaborate-to-advance-research-into-alcohol-related-liver-disease-302589479.html
SOURCE Oracle
FAQ
What did Oracle (ORCL) and Baylor announce on October 21, 2025 regarding alcohol-related liver disease?
How large is the Oracle Health real-world dataset Baylor will use for ALD research?
How many patients does Baylor plan to include in its ALD cohort using Oracle data?
What technologies will Baylor use from Oracle Health for ALD research (ORCL)?
What are the expected clinical goals of the Oracle and Baylor ALD collaboration?
